Galapagos NV announced today the achievement of a late stage discovery milestone for small molecules against a novel target in the osteoarthritis (OA) alliance with Servier.
Galapagos NV announced today the achievement of a late stage discovery milestone for small molecules against a novel target in the osteoarthritis (OA) alliance with Servier.